The insulin-like growth factors and growth disorders of childhood.

Abstract

Specific lesions of the growth hormone (GH)/insulin-like growth factor (IGF) axis have been identified in humans, each of which has distinctive auxologic and biochemical features. Measures of circulating IGF-I are useful in diagnosing growth disorders in childhood and in evaluating response to GH therapy. Recombinant human IGF-I is an effective treatment of severe primary IGF deficiency, which is typical of patients with GH receptor defects (Laron syndrome). Such treatment has been limited to a few severely affected patients. Future studies will provide new insight into IGF-I as treatment and into the nature of growth disorders that involve the IGF axis.

• Authors: Philippe F Backeljauw, Steven D Chernausek
• Journal: Endocrinology and metabolism clinics of North America (Endocrinol Metab Clin North Am) Vol. 41 Issue 2 Pg. 265-82, v (Jun 2012) ISSN: 1558-4410 [Electronic] United States
• PMID: 22682630 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2012 Elsevier Inc. All rights reserved.

Chemical References

• Insulin-Like Growth Factor Binding Proteins
• Intercellular Signaling Peptides and Proteins
• Recombinant Proteins
• Somatomedins
• myotrophin

Topics

• Child
• Female
• Growth Disorders (diagnosis, drug therapy, metabolism)
• Humans
• Insulin-Like Growth Factor Binding Proteins (blood, physiology)
• Intercellular Signaling Peptides and Proteins (therapeutic use)
• Laron Syndrome (drug therapy, metabolism)
• Male
• Recombinant Proteins (therapeutic use)
• Somatomedins (deficiency, genetics, therapeutic use)
• Treatment Outcome